Acadia Pharmaceuticals (ACAD) Retained Earnings (2010 - 2026)
Acadia Pharmaceuticals (ACAD) recorded quarterly Retained Earnings of -$563000.0 in Q1 2026, up 99.97% quarter-over-quarter from -$1.8 billion in Q4 2025, and up 99.97% on a YoY basis from -$281536.3 in Q1 2025.
Acadia Pharmaceuticals (ACAD) Retained Earnings (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Retained Earnings history runs 17 years deep, the most recent figure standing at -$563000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 99.97% year-over-year to -$563000.0; the TTM figure through Mar 2026 stood at -$563000.0 (up 99.97% YoY), while the FY2025 annual figure was -$1.8 billion, down 621122.6% from the prior year.
- Retained Earnings was -$563000.0 for Q1 2026 at Acadia Pharmaceuticals, up from -$1.8 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $858000.0 in Q3 2024 to a low of -$2.4 billion in Q4 2023.
- Historically, Retained Earnings has averaged -$1.5 billion across 5 years, with a median of -$2.2 billion in 2025.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings plunged 1234041.15% in 2022, then soared 368.97% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$2.4 billion in 2022, then slipped by 2.59% to -$2.4 billion in 2023, then surged by 100.01% to $292000.0 in 2024, then tumbled by 621122.6% to -$1.8 billion in 2025, then jumped by 99.97% to -$563000.0 in 2026.
- The last three Retained Earnings figures came in at -$563000.0 (Q1 2026), -$1.8 billion (Q4 2025), and -$2.1 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Acadia Pharmaceuticals | 3.68 Bn | 2.83 Bn | 243.27 Mn | -563,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -563,000.00 |
| Dec 31, 2025 | -1.81 Bn |
| Sep 30, 2025 | -2.09 Bn |
| Jun 30, 2025 | -2.16 Bn |
| Mar 31, 2025 | -2.19 Bn |
| Dec 31, 2024 | 292,000.00 |
| Sep 30, 2024 | 858,000.00 |
| Jun 30, 2024 | -339,000.00 |
| Mar 31, 2024 | -2.41 Bn |
| Dec 31, 2023 | -2.43 Bn |
| Sep 30, 2023 | -319,000.00 |
| Jun 30, 2023 | -2.41 Bn |
| Mar 31, 2023 | -2.41 Bn |
| Dec 31, 2022 | -2.37 Bn |
| Sep 30, 2022 | -1.37 Mn |
| Jun 30, 2022 | -2.30 Bn |
| Mar 31, 2022 | -2.27 Bn |
| Dec 31, 2021 | -192,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | -2.10 Bn |